Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections

Drug, Healthcare and Patient Safety

Volumn 2, Issue 1, 2010, Pages 27-38

  Neofytos, Dionissios ^a   Avdic, Edina ^b   Magiorakos, Anna Pelagia ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

Adverse events; Drug drug interactions; Fluconazole; Invasive fungal infections; Itraconazole; Posaconazole; Review; Triazoles; Voriconazole

Indexed keywords

ALBACONAZOLE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CIMETIDINE; CYTOCHROME P450; DIGOXIN; DISOPYRAMIDE; EFAVIRENZ; ESOMEPRAZOLE; FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; METOCLOPRAMIDE; MICONAZOLE; NEVIRAPINE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; POSACONAZOLE; PROTEINASE INHIBITOR; RAVUCONAZOLE; RIFABUTIN; RIFAMPICIN; RITONAVIR; THEOPHYLLINE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE;

AGITATION; ALOPECIA; ANTIFUNGAL ACTIVITY; AUDITORY HALLUCINATION; BIOAVAILABILITY; BLURRED VISION; CENTRAL NERVOUS SYSTEM INFECTION; CHEILITIS; CHOLESTASIS; CLINICAL TRIAL; COLOR VISION DEFECT; CONFUSION; CONGENITAL DISORDER; CONGESTIVE HEART FAILURE; CYSTIC FIBROSIS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACE ERYTHEMA; GASTROINTESTINAL TOXICITY; HEPATITIS; HUMAN; HYPERPIGMENTATION; HYPOKALEMIA; HYPOTENSION; IRRITABILITY; LABORATORY TEST; LIVER FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MEDICAL RECORD; MUSCLE HYPOTONIA; NAUSEA; NEUROTOXICITY; NONHUMAN; PATIENT MONITORING; PERIPHERAL EDEMA; PHOTOPHOBIA; PHOTOSENSITIVITY DISORDER; PRURITUS; PSEUDOPORPHYRIA; QT PROLONGATION; REVIEW; SIDE EFFECT; SKIN TOXICITY; SYSTEMIC MYCOSIS; TERATOGENICITY; VISUAL DISORDER; VISUAL HALLUCINATION; VOMITING;

EID: 77953472659     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/dhps.s6321     Document Type: Review

References (101)

1. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(7):909-917.
2. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30(6):851-856.
3. Marr KA. Fungal infections in hematopoietic stem cell transplant recipients. Med Mycol. 2008;46(4):293-302.
4. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175(6):1459-1466.
5. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: Outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44(4):531-540.
6. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: Biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47(8):1041-1050.
7. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545-1552.
8. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845-851.
9. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331(20):1325-1330.
10. Louie A, Drusano GL, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother. 1998;42(5):1105-1109.
11. Klepser ME, Malone D, Lewis RE, Ernst EJ, Pfaller MA. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother. 2000;44(7):1917-1920.
12. Andes D, Marchillo K, Conklin R, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother. 2004;48(1):137-142.
13. Diflucan [Package insert]. New York, NY: Roerig, 2008.
14. Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol. 1994;46(2):147-150.
15. Sporanox [Package insert]. Raritan, NJ: PriCara, 2009.
16. Prentice AG, Warnock DW, Johnson SA, Phillips MJ, Oliver DA. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother. 1994;34(2):247-252.
17. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003;37(5):728-732.
18. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004;122(1):42-47.
19. Vfend [Package insert]. New York, NY: Roerig, 2008.
20. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46(8):2546-2553.
21. Noxafil [Package insert]. Kenilworth, NJ: Schering-Plough, 2008.
22. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol. 2004;57(2):218-222.
23. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: Comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet. 2005;44(2):211-220.
24. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50(2):658-666.
25. Ruping MJ, Albermann N, Ebinger F, et al. Posaconazole concentrations in the central nervous system. J Antimicrob Chemother. 2008;62(6):1468-1470.
26. Reinwald M, Uharek L, Lampe D, Grobosch T, Thiel E, Schwartz S. Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis. Bone Marrow Transplant. 2009;44(4):269-270.
27. Horn D, Neofytos D, Fishman J, et al. Use of the PATH alliance database to measure adherence to IDSA guidelines for the therapy of candidemia. Eur J Clin Microbiol Infect Dis. 2007;26(12):907-914.
28. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis. 2006;43(1):25-31.
29. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327-360.
30. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503-535.
31. Olyaei A. Focus in Fungal Infections, 19 meeting: An analysis of antifungal dosing patterns from a cohort of more than 6900 patients at 74 North American centers (2004-2008); March 4-6, 2009, Fort Myers, FL.
32. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev. 2003;35(2-3):99-106.
33. Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009;49(2):196-204.
34. Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med. 2008;29(2):198-210.
35. Cohen LG, DiBiasio A, Lisco SJ, Hurford WE. Fluconazole serum concentrations and pharmacokinetics in an obese patient. Pharmacotherapy. 1997;17(5):1023-1026.
36. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37(6):535-540.
37. Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A. Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese subjects. Int J Clin Pharmacol Res. 1994;14(3):87-93.
38. Barone JA, Moskovitz BL, Guarnieri J, et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy. 1998;18(2):295-301.
39. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201-211.
40. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother. 2004;48(3): 804-808.
41. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother. 2006;50(5):1881-1883.
42. Kosoglou T, Perentesis GP, Affrime MB, et al. The effect of antacid and cimetidine on the oral absorption of the antifungal agent SCH 39304. J Clin Pharmacol. 1990;30(7):638-642.
43. Jain R, Pottinger P. The effect of gastric acid on the absorption of posa-conazole. Clin Infect Dis. 2008;46(10):1627; author reply 1627-1628.
44. Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis. 2009;48(6):839.
45. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335-347.
46. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007;27(12):1627-1636.
47. Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy. 2008;28(10):1223-1232.
48. Nicolau DP, Crowe H, Nightingale CH, Quintiliani R. Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother. 1995;36(2):395-401.
49. Ong DL, Fobes LM. Administering itraconazole via nasogastric tube. Am J Health Syst Pharm. 1996;53(16):1962.
50. Martinez V, Le Guillou JL, Lamer C, Le Jouan M, Tod M, Dromer F. Serum voriconazole levels following administration via percutaneous jejunostomy tube. Antimicrob Agents Chemother. 2003;47(10):3375.
51. Grau S, Mateu-De AJ, Alvarez-Lerma F, Marin-Casino M, Torres-Rodriguez JM. Successful treatment of an aspergillus fumigatus infection with voriconazole via a nasogastric tube. J Chemother. 2006;18(4):445-446.
52. Dodds Ashley ES, Varkey JB, Krishna G, et al. Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. Antimicrob Agents Chemother. 2009;53(7): 2960-2964.
53. Berge M, Guillemain R, Boussaud V, et al. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl Infect Dis. 2009;11(3):211-219.
54. Lee BE, Feinberg M, Abraham JJ, Murthy AR. Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr Infect Dis J. 1992;11(12):1062-1064.
55. Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis. 1996;22(2):336-340.
56. Sorensen HT, Nielsen GL, Olesen C, et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol. 1999;48(2):234-238.
57. Norgaard M, Pedersen L, Gislum M, et al. Maternal use of fluconazole and risk of congenital malformations: A Danish population-based cohort study. J Antimicrob Chemother. 2008;62(1):172-176.
58. Tiboni GM. Second branchial arch anomalies induced by fluconazole, a bis-triazole antifungal agent, in cultured mouse embryos. Res Commun Chem Pathol Pharmacol. 1993;79(3):381-384.
59. Bar-Oz B, Moretti ME, Bishai R, et al. Pregnancy outcome after in utero exposure to itraconazole: A prospective cohort study. Am J Obstet Gynecol. 2000;183(3):617-620.
60. De Santis M, Di Gianantonio E, Cesari E, Ambrosini G, Straface G, Clementi M. First-trimester itraconazole exposure and pregnancy outcome: A prospective cohort study of women contacting teratology information services in Italy. Drug Saf. 2009;32(3): 239-244.
61. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26(12): 1730-1744.
62. Pappas PG, Kauffman CA, Perfect J, et al. Alopecia associated with fluconazole therapy. Ann Intern Med. 1995;123(5):354-357.
63. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001;357(9270):1766-1767.
64. Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, Graybill JR. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother. 1991;35(4):707-713.
65. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33(9):1447-1454.
66. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003;22(11):651-655.
67. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med. 2006;119(6):527,e17-e24.
68. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346(4): 225-234.
69. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trial. Lancet. 2005;366(9495):1435-1442.
70. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-415.
71. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563-571.
72. Denning DW, Griffiths CE. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol. 2001;26(8):648-653.
73. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46(2):235-243.
74. Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin Infect Dis. 2008;47(1):e7-e10.
75. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: Evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006;136(45-46):739-742.
76. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33(9):1447-1454.
77. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003;22(11):651-655.
78. Rubenstein M, Levy ML, Metry D. Voriconazole-induced retinoidlike photosensitivity in children. Pediatr Dermatol. 2004;21(6): 675-678.
79. Vandecasteele SJ, Van Wijngaerden E, Peetermans WE. Two cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazole. Eur J Clin Microbiol Infect Dis. 2004;23(8): 656-657.
80. Dolan CK, Hall MA, Blazes DL, Norwood CW. Pseudoporphyria as a result of voriconazole use: A case report. Int J Dermatol. 2004;43(10):768-771.
81. Racette AJ, Roenigk HH Jr, Hansen R, Mendelson D, Park A. Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl. J Am Acad Dermatol. 2005;52(5 Suppl 1): S81-S85.
82. Tolland JP, McKeown PP, Corbett JR. Voriconazole-induced pseudoporphyria. Photodermatol Photoimmunol Photomed. 2007;23(1): 29-31.
83. Kwong WT, Hsu S. Pseudoporphyria associated with voriconazole. J Drugs Dermatol. 2007;6(10):1042-1044.
84. McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis. 2007;44(5):e55-e56.
85. Malani AN, Aronoff DM. Voriconazole-induced photosensitivity. Clin Med Res. 2008;6(2):83-85.
86. Alexander BD, Perfect JR, Daly JS, et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation. 2008;86(6):791-796.
87. Hachem RY, Langston AA, Graybill JR, et al. Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. J Antimicrob Chemother. 2008;62(6):1386-1391.
88. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis. 2007;44(1):2-12.
89. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother. 1988;32(9): 1310-1313.
90. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(7): 807-825.
91. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis. 2008;21(6):580-586.
92. Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother. 2008;42(12):1859-1864.
93. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109(8):1532-1535.
94. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007;40(5): 451-456.
95. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005;35(5):509-513.
96. Baden LR, Katz JT, Fishman JA, et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation. 2003;76(11): 1632-1637.
97. Moton A, Krishna G, Wang Z. Tolerability and safety profile of posaconazole: Evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther. 2009;34(3):301-311.
98. Raad II, Hanna HA, Boktour M, et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: Posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia. 2008;22(3):496-503.
99. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-359.
100. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006;42(12):1726-1734.
101. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42(10): 1398-1403.